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Abstract
Epidemiological studies have reported inconsistent associations between telomere length (TL) and risk for various cancers.
These inconsistencies are likely attributable, in part, to biases that arise due to post-diagnostic and post-treatment TL
measurement. To avoid such biases, we used a Mendelian randomization approach and estimated associations between nine
TL-associated SNPs and risk for ﬁve common cancer types (breast, lung, colorectal, ovarian and prostate cancer, including
subtypes) using data on 51 725 cases and 62 035 controls. We then used an inverse-variance weighted average of the SNP-
speciﬁc associations to estimate the association between a genetic score representing long TL and cancer risk. The long TL
genetic score was signiﬁcantly associated with increased risk of lung adenocarcinoma (P = 6.3 × 10−15), even after exclusion of a
SNP residing in a known lung cancer susceptibility region (TERT-CLPTM1L) P = 6.6 × 10−6). Under Mendelian randomization
assumptions, the association estimate [odds ratio (OR) = 2.78] is interpreted as theOR for lungadenocarcinomacorresponding to
a 1000 bp increase in TL. The weighted TL SNP score was not associated with other cancer types or subtypes. Our ﬁnding that
genetic determinants of long TL increase lung adenocarcinoma risk avoids issues with reverse causality and residual
confounding that arise in observational studies of TL and disease risk. Under Mendelian randomization assumptions, our
ﬁnding suggests that longer TL increases lung adenocarcinoma risk. However, caution regarding this causal interpretation is
warranted in light of the potential issue of pleiotropy, and a more general interpretation is that SNPs inﬂuencing telomere
biology are also implicated in lung adenocarcinoma risk.
Introduction
Telomeres are DNA–protein complexes at chromosome ends that
help maintain genome stability by protecting DNA from damage
and fusion. The DNA component is a six-base TTAGGG repeat se-
quence that shortens with each cell division. In differentiated
cells, telomere shortening eventually leads to loss of telo-
mere protection and genome instability, typically triggering cell
senescence or programmed cell death (1). In stem and progenitor
cells, the telomerase enzyme elongates telomeres, enabling
prolonged cell survival (2). Telomerase is also activated in >90%
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of human tumors (3), which typically have short telomeres (a po-
tential cause of genome instability), thus promoting proliferation
and survival (4).
The critical role of telomeres and telomerase in carcinogenesis
has led to the hypothesis that short telomere length (TL) is a risk
factor for cancer (5). Indeed, short relative TLmeasured in surrogate
tissues, such as peripheral blood cells, has been associatedwith in-
creased risk for lung (6,7), ovarian (8), colorectal (9) and breast can-
cers (10,11) in epidemiological studies (with the interpretation that
blood TL predicts cancer risk because it is a proxy for TL in cancer-
prone tissues). However, such associations are not consistent
across all cancers or even within cancer types, with some studies
reporting null, U-shaped or positive associations (11–16). Further-
more, due to the retrospective nature of case–control studies from
which many of these association estimates are obtained, telomere
shortening that occurs after diagnosis, potentially due to treatment
(17,18) or disease progression, can result in biased estimates of the
association between TL and cancer risk (6,8,14).
Genome-wide association (GWA) studies have identiﬁed sev-
eral genomic regions containing variants associated with TL in
peripheral blood cells (19–21), including the TERT (telomerase re-
verse transcriptase) region (5p15.33). Furthermore, GWA studies
of cancer risk have observed that variants in the TERT region in-
ﬂuence risk for multiple cancer types, including breast (22), colo-
rectal (23), lung (24), prostate (24) and ovarian (22) cancer,
although these associations do not appear to all be driven by
the same causal variant. In light of this evidence indicating an
important role for telomeres in carcinogenesis, we undertook a
comprehensive examination of associations between genetic de-
terminants of TL and cancer risk.
In this work, we describe the associations between nine TL-
associated genetic variants and risk for ﬁve cancer types (breast,
lung, colorectal, ovarian and prostate), using data from the Gen-
etic Associations and Mechanisms in Oncology (GAME-ON) net-
work of consortia for post-GWA research. In addition, we
estimate the association between a multi-variant TL score and
cancer risk, which corresponds to the effect of TL on cancer risk
underMendelian randomization assumptions (25). However, this
interpretation requires caution because the validity of the
Mendelian randomization assumptions (such as the absence of
pleoitropy) cannot be proven.
Because genotype–phenotype associations are not vulnerable
to biases caused by reverse causation or confounding by environ-
ment, the Mendelian randomization approach used in this study
is an attractive approach for estimating relationships between
TL and cancer risk.
Results
The Genetic Associations and Mechanisms in Oncology (GAME-
ON) Consortium is a network of ﬁve consortia focused on cancers
of the breast, colon, lung, ovary and prostate. The GAME-ON net-
work represents 33 GWA studies contributing data on >51 000
cancer cases and >62 000 controls (26). Samples sizes for each
cancer type and subtype are listed in Table 1.
Association estimates for individual SNPs
Based on the existing literature, we identiﬁed nine SNPs showing
genome-wide signiﬁcant associations (P < 5 × 10−8) with TL in
GWA studies (19–21). From these prior papers we obtained the
identiﬁer for the lead SNP at each reported locus as well as the
‘long TL’ allele, association estimate for the ‘long’ allele (in
Table 1. Sample sizes for cancer types included in the Genetic
Associations and Mechanisms in Oncology (GAME-ON) consortium.
Details on the GAME-ON Network and the contributing GWA
studies have been previously described (26) (http://epi.grants.
cancer.gov/gameon/)
Cancer type Cases Controls GWA studiesa
Breast
All 15 748 18 084 11
ER-negative 4939 13 128 8
Colorectal 5100 4831 6
Lungb
All 12 160 16 838 9
Adenocarcinoma 3718 15 871 9
Squamous 3422 16 015 9
Ovarian
All 4369 9123 3
Clear-cell 356 9123 3
Endometrioid 715 9123 3
Serous 2556 9123 3
Prostate
All 14 160 12 724 6
Aggressive 4450 12 724 6
aNot including studies from the Genetics and Epidemiology of Colorectal Cancer
Consortium (GECCO).
bSubtypes listed do not represent all subtypes within cancer type.
Table 2. Characteristics of genetic variants associated with TL as reported in prior GWA studies
SNP identiﬁer Chromosome Locus ‘Long’ allele β estimatea P-value Source
rs10936599 3 TERC C 0.117 2.5 × 10−31 Codd et al. (19)
rs2736100 5 TERT C 0.094 4.4 × 10−19 Codd et al. (19)
rs7726159b 5 TERT A 0.073 4.7 × 10−17 Pooley et al. (21)
rs7675998 4 NAF1 G 0.090 4.3 × 10−16 Codd et al. (19)
rs9420907 10 OBFC1 C 0.083 6.9 × 10−11 Codd et al. (19)
rs6772228 3 PXK T 0.120 3.9 × 10−10 Pooley et al. (21)
rs8105767 19 ZNF208 G 0.058 1.1 × 10−9 Codd et al. (19)
rs755017 20 RTEL1 G 0.074 6.7 × 10−9 Codd et al. (19)
rs412658c 19 ZNF676 T 0.050 9.8 × 10−9 Mangino et al. (20)
rs3027234 17 CTC1 C 0.057 2.3 × 10−8 Mangino et al. (20)
rs11125529 2 ACYP2 A 0.067 4.5 × 10−8 Codd et al. (19)
aReported in kb telomere per ‘long’ allele.
bIn linkage disequilibrium (r2 = 0.382) with rs2736100 of the TERT locus, excluded from all analyses.
cIn linkage disequilibrium(r2 = 0.704) with rs8105767 of the ZNF208 locus, excluded from all analyses.
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terms of kb of TL per allele), and the standard error and P-value
for each SNP’s association with TL (Table 2). We estimated asso-
ciations between each of the nine TL-associated SNPs and risk for
each of the ﬁve common cancer types and subtypes in the GAME-
ON study, shown as forest plots in Supplementary Material,
Figure S1. Of note, for all nine SNPs, the long TL allele had an OR
> 1 for lung adenocarcinoma, with four of the nine associations
being statistically signiﬁcant (P < 0.05) (Fig. 1, top left). In contrast,
no TL-associated SNP was signiﬁcantly associated with squa-
mous cell carcinoma of the lung (Fig. 1, bottom left). Prostate can-
cer risk also showed nominally signiﬁcant positive associations
with the long TL alleles for three of the nine SNPs (P < 0.05)
(Supplementary Material, Fig. S1).
Mendelian randomization estimates based on multi-SNP
scores
Weestimated the associations between amulti-SNP TL score and
risk for each cancer (Table 3) using a previously described Men-
delian randomization approach that obtains an estimate using
an inverse-variance weighted average of SNP-speciﬁc associa-
tions (27,28) (see Materials and Methods). Of note, we identiﬁed
a highly statistically signiﬁcant association between long TL
and increased risk of lung adenocarcinoma with an odds ratio
(OR) of 2.78 per 1 kb increase TL [95% conﬁdence interval (CI)
2.16, 3.58; P = 6.3 × 10−15]. However, we observed no such associ-
ation for squamous cell carcinoma of the lung. Associations for
these two lung cancer subtypes are displayed in Figure 1 (right)
as solid red lines (slope = ln(OR)) overlaid on the association esti-
mates for the nine SNPs that were used to generate the OR. A
positive slope indicates that longer TL is associated with in-
creased cancer risk, while a negative slope indicates that longer
TL is associated with decreased risk. The correlation (r) between
the magnitude of the SNPs’ associations with TL and the magni-
tude of the SNPs’ associations with adenocarcinoma risk was
0.17. Other than lung adenocarcinoma, no other cancer types
showed a statistically signiﬁcant association with the multi-
SNP score. However, prostate cancer risk showed suggestive
evidence of positive association with long TL with a Mendelian
randomization OR of 1.21 per 1 kb increase in TL (95% CI 0.99,
1.46; P = 0.06). Scatter plots for all cancer types are displayed in
Supplementary Material, Figure S2.
Additional age- and sex-stratiﬁed analyses were conducted
for overall lung cancer, with ﬁndings indicating similar estimates
Figure 1. Forest plots (left) and scatter plots (right) of associations between TL-associated SNPs and risk for lung adenocarcinoma (top) and squamous cell carcinoma
(bottom). Forest plots show association estimates (with horizontal bars indicating 95% CI) for the ‘long telomere’ allele of each SNP with cancer risk. SNPs are ordered
by increasing magnitude of association with TL. Scatter plots show the per-allele association with cancer risk plotted against the per-allele association with kb of TL
(with vertical and horizontal black lines showing 95% cCI for each SNP). The scatter plot is overlaid with the Mendelian randomization estimate (slope of red solid line
with dotted lines showing 95% CI) of the effect of TL on cancer risk
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for younger subjects (≤50 years old) (OR = 1.95; 95% CI 1.19, 3.21;
P = 0.008) and older subjects (>50 years old) (OR = 1.78; 95% CI
1.47, 2.15; P = 2.98 × 10−9) and similar estimates formen (OR = 1.72;
95% CI 1.38, 2.14; P = 1.06 × 10−6) and women (OR = 1.99; 95% CI
1.42, 2.77; P = 5.3 × 10−5).
In addition to the inverse-variance weighted approach for ob-
taining Mendelian randomization estimates, we also used a like-
lihood-based Mendelian randomization method (28). Both
methods produced very similar estimates for all cancer types, al-
though the lung adenocarcinoma estimates variedmore between
the twomethods comparedwith the other cancer types (Table 3).
Sensitivity analyses
The estimates reported above can only be interpreted as the causal
effect of averageTLon cancer riskwhen theMendelian randomiza-
tion assumptions are valid—namely, when (1) the SNPs from the
literature are truly predictive of TL in the cancer-prone tissue, (2)
the SNPs are not associated with other factors (confounders) that
inﬂuence both TL and cancer risk and (3) the SNPs only affect can-
cer risk through their effects onTL, i.e. there are no alternative cau-
sal pathways by which the SNPs inﬂuence cancer risk. Violation of
any of the assumptions can result in a biased causal estimate for
the effect of TL on cancer risk. We performed sensitivity analyses
in which SNPs were excluded from the multi-SNP score based on
potential violation of these assumptions.
To assess a potential violation of the ﬁrst assumption, an add-
itional analysis was performed after excluding the SNP near the
PXK region (rs6772228), whichmay be a false-positive association
evidenced by its lack of plausible biological explanation, and the
lack of consistency in its association with TL across several study
sites (21). This ‘strict’ analysis resulted in a notable difference
only for prostate cancer risk, which now showed a statistically
signiﬁcant estimate (OR 1.27; 95% CI 1.03, 1.54; P = 0.02) (Supple-
mentary Material, Table S1).
To assess potential violation of the second and third assump-
tions, an additional analysis was performed including only SNPs
for which themagnitude of association with cancer risk appeared
to be proportional to themagnitude of associationwith TL. Under
Mendelian Randomization assumptions two and three, the ratio
of the SNP-cancer association to the SNP–TL association for each
SNP should be similar for all SNPs used in the SNP score. An inﬂa-
tion of the ratio for any single SNP may be an indication that the
SNPexerts a pleiotropic effect on cancer that is unrelated to its ef-
fect on TL. Deviation from this expectation is tested using a good-
ness-of-ﬁt test (29,30), in which SNPs that exhibit evidence of
pleiotropy due to an inﬂated SNP–cancer to SNP–TL ratio can be
detected and excluded from Mendelian randomization analyses
(see Materials and Methods).
The exclusion of SNPs that failed the goodness-of-ﬁt test
(Supplementary Material, Table S2) resulted in two notable ﬁnd-
ings (Supplementary Material, Table S1). First, exclusion of the
SNPs in the TERTandCTC1 regions from the SNP set used for over-
all prostate cancer resulted in a stronger, statistically signiﬁcant
association (OR = 1.45; 95%CI 1.18, 1.82; P = 7.9 × 10−4). Second, the
exclusion of the SNP in the TERT region from the SNP set used for
lung adenocarcinoma resulted in a somewhat attenuated associ-
ation, but the association remained statistically signiﬁcant: (OR =
2.00, 95% CI 1.48, 2.70, P = 6.6 × 10−6). Lung adenocarcinoma had a
signiﬁcant heterogeneity test statistic (Supplementary Material,
Table S2), which likely explains why there was a difference in
the estimates obtained using the inverse-variance weighted
method and the likelihood method noted earlier; the optimiza-
tion algorithm of the likelihood-based method can have poor
convergence when the heterogeneity statistic is strongly signiﬁ-
cant (28). This difference in estimates betweenmethods is elimi-
nated after excluding the TERT SNP (rs2736100) that drives the
heterogeneity in association estimates for lung adenocarcinoma.
Discussion
In this analysis of cancer risk across ﬁve cancer-prone organs, we
observed that a multi-SNP score for long telomeres was signiﬁ-
cantly associated with increased risk of lung adenocarcinoma
(but not squamous cell carcinoma) and suggestively associated
with increased risk of prostate cancer. We did not observe an as-
sociation between themulti-SNP score and risk of breast, colorec-
tal or ovarian cancer (including subtypes). Under Mendelian
randomization assumptions, the associations reported here can
be interpreted as effects of TL on cancer risk, although caution re-
garding such an interpretation is warranted because the validity
of these assumptions (such as the absence of pleiotropy) cannot
Table 3.ORs of cancer risk per 1000 bp increase in TL according to amulti-SNP TL score using the inverse-varianceweightedmethod (left) and the
likelihood method (right)
Inverse-variance weighted method Likelihood method
Cancer type OR 95% CI P-value OR 95% CI P-value
Breast
All 1.02 0.86, 1.21 0.82 1.02 0.86, 1.21 0.81
ER-negative 1.05 0.81, 1.38 0.70 1.05 0.80, 1.38 0.70
Colorectal 1.25 0.92, 1.69 0.15 1.26 0.92, 1.71 0.15
Lung
All 1.65 1.39, 1.96 1.3 × 10−8 1.67 1.40, 2.00 1.3 × 10−8
Adenocarcinoma 2.87 2.20, 3.74 6.3 × 10−15 3.03 2.29, 4.01 8.2 × 10−15
Squamous 1.04 0.79, 1.36 0.79 1.04 0.79, 1.36 0.79
Ovarian
All 1.13 0.87, 1.47 0.37 1.13 0.87, 1.48 0.36
Clear-cell 1.65 0.78, 3.51 0.19 1.68 0.78, 3.61 0.19
Endometrioid 1.30 0.75, 2.24 0.35 1.30 0.75, 2.25 0.35
Serous 1.19 0.86, 1.65 0.30 1.19 0.86, 1.66 0.29
Prostate
All 1.21 0.99, 1.46 0.06 1.22 1.00, 1.48 0.06
Aggressive 1.10 0.83, 1.45 0.52 1.10 0.83, 1.46 0.51
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be proven. Our resultswere consistent using two different analyt-
ic approaches. After performing sensitivity analyses in which
SNPs were excluded from themulti-SNP score based on potential
violation of Mendelian randomization assumptions, the associ-
ation with prostate cancer risk became statistically signiﬁcant.
In addition, the exclusion of the SNP in the TERT region (a
known susceptibility locus for lung cancer) from the lung adeno-
carcinoma analysis resulted in an attenuated but still highly stat-
istically signiﬁcant association, indicating that the observed
association is not solely driven by the SNP in the TERT region.
Even after dropping the three SNPs showing nominally signiﬁ-
cant (P < 0.05) association with lung adenocarcinoma (in TERT,
OBFC1 and NAF1) the association is still signiﬁcant (OR = 1.54,
P = 0.018).
Several epidemiologic studies have examined the association
between leukocyte TL and lung cancer risk. Three retrospective
case–control studies reported an association between long TL
and decreased lung cancer risk in US and Korean subjects
(7,31,32). However, a fourth stratiﬁed retrospective case–control
study showed a positive association between TL and adenocar-
cinoma risk but an inverse association for squamous cell carcin-
oma (33). In two studies with prospective TL measurement, long
TL was found to be associated with increased overall lung cancer
risk among Caucasian male smokers (34) and East Asian female
never-smokers (13), while a large Danish general population
study found no association (12). In a pooled analysis of three pro-
spective cohort studies including the two aforementioned stud-
ies and a third study conducted in the USA, long telomeres
were associated with increased lung cancer risk, and the associ-
ation was present in adenocarcinomawhile absent in squamous
cell carcinoma (35). Consistent with ﬁndings from the prospect-
ive studies and the stratiﬁed case–control study, we observed a
positive association between the long TL SNP score and lung can-
cer risk corresponding to an OR of 1.65 per 1000 bp TL for overall
lung cancer (P = 1.3 × 10−8) and an OR of 2.87 per 1000 bp TL for
lung adenocarcinoma (P = 6.3 × 10−15) (assuming valid Mendelian
randomization assumptions). Seow et al. (35) reported the risk of
overall lung cancer between the lowest quartile andhighest quar-
tile as OR = 1.86 (95% CI 1.33–2.62), and the risk of adenocarcin-
oma cancer as OR = 2.52 (95% CI 1.38–4.60). While our estimates
are not directly comparable to these prior estimates due to differ-
ences in the scale of the TL variable (kb vs. quartiles), we used a
simple simulation to show that our estimates are similar to these
prior estimates. We simulated normally distributed TL variables
with amean of 6000 bp and standard deviations ranging from 400
to 700 bp based on values observed from the prior literature (36–
38). The difference between the mean values for quartiles one
and four ranged between 1018 and 1781 bp. We then rescaled
our ORs to correspond to a difference in 1018–1781 bp rather
than 1000 bp. The resulting estimates are OR = 1.68–2.94 for over-
all lung cancer risk between the lowest and highest quartiles, and
OR = 2.92–5.11 for lung adenocarcinoma risk between the lowest
and highest quartiles. These are comparable with the estimates
reported by Seow et al. The observed heterogeneity in our associ-
ation estimates is likely due to the two subtypes being biological-
ly distinct, having previously been characterized as having
different genetic susceptibilities (39), unique gene expression
proﬁles (40), distinct molecular features (41) and different pat-
terns of chromosomal imbalance (42).
The Asian female non-smokers among whom a TL-lung can-
cer association was observed (13) were also recently studied to
evaluate seven TL-associated SNPs in relation to lung cancer
risk (43). Consistent with our ﬁndings, the risk score for long TL
was associated with an increase in lung cancer. Furthermore,
their stratiﬁed analyses suggested a stronger association among
younger individuals ( <60 years old) and signiﬁcant associations
for both adenocarcinoma and squamous cell subtypes. In con-
trast, our stratiﬁed analyses produced similar estimates by age
and different estimates by subtype. Potential factors driving
these differences in ﬁndings may be differences in ancestry or
differences in the etiology of subtypes between the two study
populations.
A protective effect of short TL on lung cancer risk has a bio-
logically plausible explanation, as short telomeres could protect
against cancer by triggering cell senescence or programmed cell
death in the presence of functional cell cycle checkpoints and
intact apoptotic pathways (44). Conversely, long telomeres
may enable additional rounds of cell division, allowing more
opportunities for the accumulation of somatic mutations that
promote carcinogenesis, resulting in greater susceptibility to
malignant transformation (45,46). The association between
long TL SNPs and increased risk has also been previously ob-
served for melanoma (47), with a proposed mechanism being
that long telomeres increase the proliferative duration of cells,
thus delaying senescence and allowing further mutations to
occur (48).
Cigarette smoking is a potential confounder in many epide-
miologic studies of TL and cancer due to its correlation with
short TL (49). However, our study utilizes genetic variants asso-
ciated with TL as proxy for actual measured TL, and is therefore
not subject to the potential confounding effects of smoking and
other exposures. TL-outcome confounders such as smoking
would only introduce bias if the genetic variants used in the
score are also associated with smoking behavior, as it would be
a violation of the second Mendelian randomization assumption.
Smoking-related violation of Mendelian randomization assump-
tions (e.g., SNPs that inﬂuence TL through smoking behavior) is
unlikely due to the lack of an association between the TL SNP
score and squamous cell carcinoma of the lung, which would
be expected to have a stronger association with smoking-related
SNPs than adenocarcinoma (50), and due to the lack of evidence
that these SNPs inﬂuence smoking behavior based on prior GWA
studies.
There are few published studies on TL and prostate cancer
risk. In a small retrospective case–control study (51) and two pro-
spective studies (12,52), no statistically signiﬁcant association
was observed. In contrast, we observe a suggestive association
between long TL and increased risk for prostate cancer, an asso-
ciation that increases in signiﬁcance in the context of the ‘good-
ness-of-ﬁt’-based sensitivity analyses. This ﬁnding warrants
further investigation.
Results from prior studies of TL and colorectal cancer risk are
also inconsistent. An inverse association between TL and colo-
rectal cancer risk was described in two case–control studies
(9,14), while a U-shaped association (16) and three null-associa-
tions (12,14,15) were observed in prospective studies. Consistent
with the previous null-ﬁndings, our results show no signiﬁcant
association between TL and colorectal cancer risk, despite the in-
clusion of the TERC rs10936599 SNP, which was previously re-
ported to be associated with both increased TL and increased
risk of colorectal cancer (53). The null ﬁndings were also consist-
ent in an analysis of data from the Genetics and Epidemiology
of Colorectal Cancer Consortium (GECCO) (54) (Supplementary
Material, Fig. S3).
Although one prospective study showed evidence for associ-
ation between long TL and increased breast cancer risk (12),
two different meta-analyses of TL and breast cancer risk based
on multiple retrospective and prospective studies concluded
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therewas no overall evidence of association (6,8). Our ﬁndings for
overall breast cancer are in agreement with these prior null stud-
ies. In addition, we observe no association between the TL SNP
score and ER-negative breast cancer risk. For ovarian cancer,
two prior case–control studies observed an association between
longer telomeres and decreased risk (55,56), one case–control
study reported no association (57), while a prospective study
also reported no association (12). Our results for overall ovarian
cancer, as well as three subtypes, provide no evidence of associ-
ation with TL-associated SNPs. This lack of association is ob-
served despite the inclusion of SNP rs2736100 located in the
TERT region, which showed a nominally signiﬁcant association
with the serous subtype of ovarian cancer (P = 0.023) and is in
high LD (r2 = 0.8) with a SNP previously observed to be associated
with ovarian cancer (22). Estrogen has been demonstrated in ex-
perimental studies to have positive effects on telomerase activity
(58), and in epidemiologic studies estrogen has been shown to
have a positive associationwith TL (59).With estrogen as a poten-
tial confounder of the association between TL and ER-positive
breast and ovarian cancers, it will likely be difﬁcult to parse out
the speciﬁc role of TL in estrogen-related cancer risk in epidemio-
logical studies. However, Mendelian randomization estimates
such as those reported herewill not be biased due to confounding
by estrogen level. These multi-SNP null ﬁndings are similar to
what Pooley et al. (21) also observed while investigating individual
TL SNPassociationswith breast, ovarian andprostate cancer risks.
Although it is not possible to prove the validity of theMendel-
ian randomization assumptions, it is possible to conduct sen-
sitivity analyses to protect against some potential violations
of these assumptions. To address a potential violation of the
ﬁrst assumption—that the SNPs are associated with TL in our
study population—we conducted analyses excluding PXK SNP
rs6772228, whose association with TL has been questioned due
to the lack of consistency in its association across several study
sites (21). After exclusion, the results were essentially unchanged.
For overall prostate cancer, however, the association became stat-
istically signiﬁcant, lending support to the hypothesis that long TL
is associated with an increased risk of prostate cancer.
To address potential violations of the assumption that the
SNPs do not have effects on cancer risk independent of their ef-
fects on TL, we re-estimated the associations between the TL SNP
score and cancer after stepwise removal of potentially problem-
atic SNPs from the SNP set using a goodness-of-ﬁt test of the pro-
portionality of the SNPs’ associations with TL and cancer risk.
These exclusions resulted in some attenuation of the association
with lung adenocarcinoma, but did not substantially alter our
conclusions. For prostate cancer, the association with the
multi-SNP score became statistically signiﬁcant after excluding
TERT SNP rs2736100 and CTC1 SNP rs3027234. The heterogeneity
in association of SNPs in TERT and CTC1 identiﬁed by the good-
ness-of-ﬁt test suggests potential pleiotropic effects of these gen-
etic variants throughmechanisms other thanTL. The association
between TERT SNPs and breast and ovarian cancer risks via path-
ways other than TL has been previously observed (22), and poten-
tial extra-telomeric roles have previously been suggested for both
telomerase (60) and CTC1 (61), providing a plausible biological
basis for excluding the TERT and CTC1 SNPs from our analysis.
It is important to note however, that these secondary sensitivity
analyses are data-driven, and are presented as a supplement to
the primary analyses that include all nine SNPs.
There are several limitations of this work. The summary-level
data did not allow for analyses stratiﬁed by covariates of interest
such as sex and age (with the exception of lung cancer, for which
TRICL conducted stratiﬁed analyses). Additionally, our analysis
assumed a log-linear association between TL and cancer risk,
and the existence of a non-linear (e.g. U-shaped) association
may limit our ability to detect an association. Our estimates gen-
erated using Mendelian randomization are unbiased only if the
SNPs analyzed do not affect cancer risk through causal pathways
other than those involving TL. This assumption cannot be pro-
ven; however, our conﬁdence in the validity of this assumption
is strengthened by the fact that our primary ﬁnding is robust to
the exclusion of SNPs with potential pleiotropic actions based
on prior evidence (TERT) and a goodness-of-ﬁt test (Supplemen-
tary Material, Tables S1, S2) (although it is possible that the good-
ness-of-ﬁt test is underpowered to identify pleiotropic effects).
Our power to detect associations is limited by the small variance
in measured TL explained by SNPs used in this analysis (1–2%)
(62), although the GAME-ON Network provides very large sample
sizes that enable the detection of strong-to-moderate associations
(Supplementary Material, Table S3). Finally, we cannot conﬁrm
that genetic determinants of leukocyte TL also predict tissue-
speciﬁc TL due to the lack of tissue-based TL measures in GWA
studies. A potential consequence of selecting SNPs lacking tis-
sue-speciﬁc association with TL would be a bias toward the null,
reducing our power to detect associations using TL SNP scores.
However, correlations between TLmeasured in blood andTLmea-
sured in lung (63,64) and other tissues (65) have been reported (r =
0.35–0.84), consistent with the assumption that SNPs predict TL
across multiple tissues. Systematic studies on other tissue types
are needed to further address this uncertainty.
In conclusion, in this comprehensive Mendelian randomiza-
tion studyof TL and risk for common cancers,we observed ahigh-
ly signiﬁcant association between genetic determinants of long
TL and increased risk for lung adenocarcinoma. The estimates re-
ported here are not vulnerable to biases caused by reverse caus-
ation or confounding by unmeasured environmental factors,
strengthening the evidence for a causal role for TL in lung adeno-
carcinoma. However, the validity ofMendelian randomization es-
timates is dependent upon several assumptions, namely no
pleiotropic effects (independent of TL) of SNPs on the cancer
risk or confounders of the TL-cancer relationship. The multi-
SNP score for TL should be further investigated as a predictor of
adenocarcinoma of the lung, a common lung cancer subtype in
both smokers and non-smokers. Future research efforts need to
be undertaken to determine the value of telomeres as a novel
risk measure or a modiﬁable pharmacological target, with the
long-term goal of improving cancer prediction and prevention.
Materials and Methods
The GAME-ON network of consortia for post-GWA
research
The goals of the GAME-ON consortium were to pool data from
GWA studies to identify new loci, conduct functional studies to
identify causal SNPs and biological mechanisms, and to investi-
gate gene–gene and gene–environment interactions as a part of
efforts to develop risk prediction models. A secondary goal was
to test hypotheses across the centers that might illuminate com-
mon mechanisms of susceptibility. Details of GAME-ON and the
participating studies are available at http://epi.grants.cancer.gov/
gameon/, and described previously (26).
Identiﬁcation of SNPs associated with TL
We identiﬁed nine SNPs showing independent genome-wide sig-
niﬁcant associations (P < 5 × 10−8) with TL in previously published
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GWA studies among individuals of European ancestry (19–21). Al-
though there are speciﬁc cancer susceptibility regions of interest
such as the previously described TERT locus, our selection of
SNPs is based entirely on the SNPs’ ability to predict TL based
on prior literature, because predictive accuracy is directly related
to statistical power for Mendelian randomization (62). The pro-
portion of variance in measured average TL that is explained by
individual SNPs ranges from 0.06 to 0.2% (19), and is up to 1.6%
for a combined subset of four SNPs (20) (no estimate is currently
available for all nine SNPs). Based on the existing literature, we
obtained the identiﬁer for the lead SNP at each reported locus
as well as the ‘long TL’ allele, association estimate for the ‘long’
allele (in terms of kb increase in TL per allele), standard error
and P-value for each SNP’s association with TL (Table 2). Only
the lead SNP from each region was included in the analysis. Al-
though the estimates for these nine SNPs were obtained from
three different studies using two different methods (quantitative
PCR and Southern blot of the terminal restriction fragment), we
scaled the estimates to the same units (kb of TL per risk allele).
Comparability between studies is supported by previous studies
showing that T/S ratio from qPCR using the Cawthon method is
strongly correlated with mean terminal restriction fragment ob-
tained from Southern blot for non-extreme TL values (66). Data
on these nine SNPs were available as summary statistics for all
cancer types analyzed in the GAME-ON consortium, with the ex-
ception of colorectal cancer, for which we obtained proxy SNPs
based on strong linkage disequilibrium using the Broad Insti-
tute’s SNPAnnotation and Proxy Search tool (67) (Supplementary
Material, Table S4).
Statistical analysis
For each cancer type, standard ﬁxed-effectsmeta-analysismeth-
ods were used to combine results from individual GWA studies.
For each cancer type, genotyping was performed using Illumina
or Affymetrix arrays of varying densities described elsewhere
(26). Quality control steps taken include gender identity and
chromosomal anomaly check, exclusion of related individuals,
principal component-based exclusion of individuals of non-
European ancestry, exclusion of SNPs and individuals with
substantial missingness, exclusion of SNPs in Hardy–Weinberg
disequilibrium, and other sample and SNP quality measures.
For each study, imputation was performed using the 1000 Gen-
omes Project Phase 1 version 3 reference haplotypes, resulting
in up to ∼10million SNPs being available for the analysis for each
cancer type.
Associations between SNPs and cancer risk were estimated
using unconditional logistic regression adjusted for age, sex
(when applicable) and top principal components (ranging from
2 to 6 across 48 contributing GWA studies). For the lung cancer
study, the association was also adjusted for smoking pack-
years.Weperformed the analyses separately for cancer subtypes,
including breast (estrogen receptor negative), lung (adenocarcin-
oma and squamous cell), ovarian (clear cell, endometrioid and
serous) and prostate [aggressive and non-aggressive as previous-
ly deﬁned (68)].We performed age- and sex-stratiﬁed analyses for
overall lung cancer, for which only SNPs imputed to the Illumina
500 K array using the HapMap2 reference panel were available
across all sites. For the TL SNPs not available on the 500 K array,
wewere able to identify tag SNPs (r2 > 0.8) for all SNPs except PXK
SNP rs6772228 (Supplementary Material, Table S5).
We estimated the association between a multi-SNP TL score
and risk for each cancer using two different Mendelian random-
ization methods that require only summarized association
estimates for each SNP (hence, no actual score is created for
each individual, but we estimated the association that would be
observed for such as score if individual-level data were used).
This approach is appropriate given that the consortium provides
only summary estimates rather than individual-level data for
SNP associations. The ﬁrst method is an inverse-variance
weighted average of SNP-speciﬁc associations that has been de-
scribed previously (27,28). The Mendelian randomization esti-
mate β^IVW, and its standard error SEðβ^IVWÞ were calculated using
the following equations:
β^IVW ¼
P
k XkYkσ
2
YkP
k X
2
kσ
2
Yk
; ð1Þ
SE(β^IVWÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1P
k X
2
kσ
2
Yk
s
; ð2Þ
where Xk is the per-allele estimate of the kth SNP on TL, Yk is the
per-allele estimate of the SNP on the log-odds of cancer and σYk is
the corresponding standard error. A schematic summarizing the
aforementioned steps is shown in Supplementary Material,
Figure S4.
The second method is a likelihood-based method that has
been described previously (28). In brief, TL and cancer risk were
jointly modeled using a bivariate normal distribution for each
genetic variant. The model parameters, including a joint linear
effect between TL and cancer log-odds, were estimated using
maximum likelihood on the observed data. The likelihood-
based analyses were performed using web-based software (http://
spark.rstudio.com/sb452/summarized/) (28).
The estimates obtained from the methods described above
can be interpreted as the effect of average TL on cancer risk
under the following assumptions as previously described for cau-
sal inference based on Mendelian randomization (25): (1) the
SNPs from the literature are truly predictive of TL in the cancer-
prone tissue, (2) the SNPs are not associated with other factors
(confounders) that inﬂuence both TL and cancer risk and (3) the
SNPs only affect cancer risk through their effects on TL, i.e. there
are no alternative causal pathways by which the SNPs inﬂuence
cancer risk.
To visualize the association results for the SNP score, we plot-
ted the association between each SNP and cancer risk against as-
sociations with TL (based on the prior literature). Under the
assumption that a SNP’s association with TL is proportional to
its association with cancer risk, one would expect the plotted
points to fall along a line that passes through the origin and
has a slope equal to the Mendelian randomization estimate.
Thus, a steeper slope indicates a stronger magnitude of associ-
ation betweenTL and cancer risk. Conversely assuming no causal
effect of TL on cancer risk, the Mendelian randomization esti-
mate would correspond to a slope of zero.
To assess a potential violation of the ﬁrst assumption (i.e.,
a true association between each of the variant and TL), an add-
itional analysis was performed after excluding the SNP near the
PXK region (rs6772228), whichmay be a false-positive association
evidenced by its lack of plausible biological explanation, and the
lack of consistency in its association with TL across several study
sites (21). This analysis is referred to as the ‘strict’ analysis. To as-
sess potential violation of the second and third assumptions (i.e.,
no confounding or pleiotropy), a goodness-of-ﬁt test was per-
formed for each SNP set under the null hypothesis that each
SNP included in the SNP score has an association with cancer
risk that is proportional to its association with TL. The rejection
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of the null hypothesis indicated heterogeneity of the associations
between SNPs and cancer risk relative to the associations be-
tween the SNPs and TL. In instances where the null hypothesis
was rejected, stepwise removal of SNPs from the SNP setwas per-
formed until there was no signiﬁcant heterogeneity, based on a
method previously described (http://cran.r-project.org/web/
packages/gtx/) (29). Speciﬁcally, For K uncorrelated SNPs,
X2k ¼
X
k
Y2kσ
2
Yk
; ð3Þ
X2rs ¼
β^IVW
SE(β^IVWÞ
 !2
; ð4Þ
in which X2k and X
2
rs are χ
2
ðkÞ and χ
2
ð1Þ distributed test statistics, re-
spectively, for the association between each cancer type and all K
SNPs under an unconstrained K degree-of-freedom model, and
for the nested 1 degree-of-freedom risk scoremodel, respectively.
Then the goodness-of-ﬁt test statistic is
Qrs ¼ X2k  X2rs; ð5Þ
inwhichQrs is χ2ðk1Þ distributed under the null hypothesis that all
K SNPs are associatedwith cancer risk with true association sizes
proportional to the associations with TL. For each analysis in
which the goodness-of-ﬁt test null hypothesis was rejected (P <
0.05), we removed the SNP that resulted in the greatest reduction
of the Qrs test statistic, and repeated the goodness-of-ﬁt test. If
still P < 0.05, we repeated the exclusion procedure until P > 0.05.
The association estimates obtained from the subsequent ana-
lysis using the remaining SNPs that pass the goodness-of-ﬁt
test is referred to as the ‘goodness-of-ﬁt based’ estimates and dis-
played in Supplementary Material, Table S1. P-values for the
goodness-of-ﬁt test before and after exclusion of SNPs, and
which SNPs were excluded for each cancer analysis for the ‘good-
ness-of-ﬁt based’ analysis are shown in Supplementary Material,
Table S2. An example for this procedure is as follows: for lung
adenocarcinoma, the inclusion of all nine SNPs results in an
OR of 2.87 (P = 6.3 × 10−15), but the goodness-of-ﬁt test P-value of
9.0 × 10−6 indicates the presence of heterogeneity with at least
one of the SNPs used in the SNP score. The TERT SNP was identi-
ﬁed to be the SNP contributing the most to this heterogeneity
(by stepwise exclusion), and once removed, resulted in a SNP
score with a goodness-of-ﬁt P-value of 0.09, indicating a lack of
substantial heterogeneity in ratio of SNP–cancer to SNP–telomere
associations across SNPs. After exclusion of the TERT SNP, we still
observe a signiﬁcant association in the same direction, albeit
attenuated (OR = 2.00, P = 6.6 × 10−6).
We performed power analyses to estimate the minimum de-
tectable magnitude of association for each cancer type given
the sample sizes available in the GAME-ON study, in terms of
OR per 1 kb increase in TL. This was done using a web-based
application (http://glimmer.rstudio.com/kn3in/mRnd/) (69), spe-
cifying 80% power, 0.05 type I error rate, and assuming the vari-
ance in TL explained by the nine SNPs is R2 = 0.01 or R2 = 0.02,
respectively. Because the web application calculates the detect-
able OR of cancer risk per one standard deviation of TL, which
is roughly equivalent to 500 bp (36,37), we exponentiated this
OR to the power of 0.5 in order to obtain the detectable OR per
1000 bp increase TL. (Supplementary Material, Table S3).
Supplementary Material
Supplementary Material is available at HMG online.
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